Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent

a technology for autoimmune diseases or allergies, applied in the field of pharmaceutical composition, can solve problems such as tissue damage and direct damage to tissues

Inactive Publication Date: 2012-12-20
OSAKA UNIV
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a therapeutic agent for treating autoimmune and allergic diseases by inhibiting the binding of a specific protein called Sema3A to another protein called NP-1 / Plexin-A1. This inhibitor can be a neutralizing antibody or a soluble version of NP-1. The therapeutic agent can be used as a marker to screen for other therapeutic agents for these diseases. The invention also provides a method for identifying the therapeutic agent using a specific test. The therapeutic agent can be administered to patients who have symptoms of these diseases to treat them.

Problems solved by technology

As a result, the immune system acts on the body's own tissue, causing tissue damage.
For example, it is believed that in chronic rheumatoid arthritis and multiple sclerosis, activated T-cells specific to a self-antigen or self-MHC complex cause localized inflammation by activating macrophages, and may even damage tissues directly.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
  • Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
  • Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent

Examples

Experimental program
Comparison scheme
Effect test

example 1

Methods

Mice

[0220]Plexin-A1− / −, Sema3K− / −, Sematic− / − and NP-1 knock-in mice with a C57BL / 6 background have already been established. OT-IITg mice were provided by Mr. W. R. Heath.

[0221]For the Sema6D− / −, a 0.6 kbp fragment comprising the second exon with start codon and the third exon were replaced with a neo resistance cassette, and a herpes simplex virus thymidine kinase (HSY-TK) gene was inserted for selecting a targeting vector from random integration. Linearized targeting plasmid DNA was transfected into embryonic stem (ES) cells by electroporation. After double selection with G418 and ganciclovir, 320 resistant clones were screened for homologous recombination of Sema6D alleles by PCR and Southern blot analysis. For the Southern blot analysis, genome DNA was isolated from wild-type and Sema6D-target ES cells and digested with EcoRI, and separated by agarose gel electrophoresis. The DNA was transferred to a nylon blotting membrane (HybondN) in accordance with the manufacturer's...

example 2

[0302]To evaluate the role of Plexin-A1 in cell migration in vivo, dendritic cells collected from wild-type or Plexin-A1 knockout mice and labeled with CFSE were adoptively transferred into the dermis of mice treated with oxazolone. The behavior of the transferred dendritic cells was then monitored.

[0303]Adoptive transfer was performed by the following methods. Dendritic cells from bone marrow were labeled for 10 minutes at 22° C. in 5 μl of CFSE (carboxyfluorescein diacetate succinimidyl ester). The cells were then washed with PBS. 1×106 dendritic cells suspended in PBS were subcutaneously injected into the foot pads of recipient mice. 24 and 48 hours after injection, the popliteal lymph nodes were collected. The lymph nodes were treated for 30 minutes at 37° C. with 1 mg / ml of collagenase D. The cell numbers were counted and analyzed by flow cytometry. As described in Cavanagh et al. (Nat. Immunol. (2005) 6, 1029-1037), the percentage of migrating dendritic cells corresponds to th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1 / Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.

Description

TECHNICAL FIELD[0001]1. Related Application[0002]This application claims priority from Japanese Patent Application No. 2009-254108 (filed on Nov. 5, 2009), contents of which are incorporated herein by reference.[0003]2. Technical Field[0004]The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or allergies, comprising as an active ingredient a substance effective for treating autoimmune diseases or allergies that inhibits binding between NP-1 and Sema3A, such as a Neuropilin-1-Fc (NP-1-Fc), Neuropilin-1 (NP-1) neutralizing antibody, Semaphorin3A (Sema3A) neutralizing antibody or the like. The present invention further relates to a therapeutic method using the pharmaceutical composition, and to a method for screening such inhibitors.BACKGROUND ART[0005]Autoimmune diseases involve a specific and continuous adaptive immune response to a self-antigen. Unlike natural immunity and adaptive immunity to external antigens, which ultimate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/28C07K14/705G01N21/76C12N5/0784G01N33/566C07K16/18C07K19/00
CPCC07K16/18C07K16/2863C07K2317/34G01N33/53G01N33/566G01N2500/04A61P1/02A61P1/04A61P1/16A61P11/00A61P15/08A61P17/00A61P17/06A61P19/02A61P19/08A61P25/00A61P27/02A61P29/00A61P37/00A61P37/02A61P37/06A61P37/08A61P5/14A61P7/04A61P7/06A61P9/00A61P3/10
Inventor KUMANOGOH, ATSUSHI
Owner OSAKA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com